Cost-effectiveness analysis of canagliflozin (CANA) versus dapagliflozin (DAPA) as an add-on to metformin (MET) in patients with type 2 diabetes mellitus (T2DM) in the united states
Abstract
Authors
C. Neslusan A. Teschemaker S. Martin M. Willis P. Johansen